Online

WCB 2021 - Online

Session Item

Saturday
May 08
08:45 - 10:00
Optimal treatment for periorificial high risk non-melanoma skin cancer
Agata Rembielak, United Kingdom;
Gerald Fogarty, Australia
0250
Debate
09:30 - 09:45
Brachytherapy a useful tool for nasal and peri-nasal tumours
Bengt Johansson, Sweden
SP-0093

Abstract

Brachytherapy a useful tool for nasal and peri-nasal tumours
Authors: Bengt Johansson(Örebro University Hospital, Oncology, Örebro, Sweden)
Show Affiliations
Abstract Text

There is an increasing incidence of Basal cell carcinoma (BCC) and Squamous cell carcinoma (SCC) on the external nose. Surgery is the main treatment but often face problems with respect to cosmetic defects and non-radical resection.

Brachytherapy (BT) can be used in the primary treatment to preserve cosmetic appearance and to treat with appropriate margins. Brachytherapy are also indicated in tumor recurrence after surgery and in case of non-radical resection.

Long-term local control rate (LCR) in literature is 90-95 %. Treatment time is short 1-2 weeks.

There are different BT techniques available such as -Surface BT (Valencia applicator or Mould BT), -interstitial BT (trans-nasal or along nasal) or a combination of both.

The choice of BT technique is depending on; -thickness of the tumor, -location on the nose (cartilage part vs bony part), - tumor growth (flat part, curvature part, exophytic part), -extension to peri-nasal areas (upper lip, cheek, medial eye corner).

Usually a full dose of BT is prescribed like 60 Gy PDR (0.83 Gy/ 2nd hour) or 45, 5 Gy HDR (3.5 Gy 2fx/d) (GEC-ESTRO recommendations for head/neck BT RTO 20016:10 and skin RTO 2018:126.) Own experience 1998-2019 in 121 patients confirms published results of 93.4 % long-term LCR.

Side effects are uncommon and include: septum perforation, telangiectasia, atrophy and sclerosis.

Multidisciplinary conferences and teaching of plastic surgeons about potential benefits of BT are fundamental to avoid unnecessary mutilation.